A Randomised, Placebo-controlled Trial of Carvedilol in Early Familial Dilated Cardiomyopathy

Heart Lung and Circulation

Volumn 20, Issue 9, 2011, Pages 566-573

  Yeoh, Thomas ^a   Hayward, Christopher ^b,c   Benson, Victoria ^b   Sheu, Angela ^a   Richmond, Zara ^a   Feneley, Michael P ^b,c   Keogh, Anne M ^b,c   Macdonald, Peter ^a,b,c   Fatkin, Diane ^a,b,c  

^a VICTOR CHANG CARDIAC RESEARCH INSTITUTE   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Beta blocker; Early disease; Familial dilated cardiomyopathy

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; NIFEDIPINE; PERINDOPRIL; PLACEBO;

ADOLESCENT; ADULT; ARTICLE; BRADYCARDIA; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FAMILIAL DISEASE; FATIGUE; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; HYPOTENSION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT DURATION; TREATMENT RESPONSE;

ADRENERGIC BETA-ANTAGONISTS; ADULT; CARBAZOLES; CARDIOMYOPATHY, DILATED; ECHOCARDIOGRAPHY; FEMALE; HEART VENTRICLES; HUMANS; MALE; MIDDLE AGED; ORGAN SIZE; PROPANOLAMINES; TIME FACTORS;

EID: 79961129032     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2011.06.004     Document Type: Article

References (31)

1. Fatkin D., Otway R., Richmond Z. Genetics of dilated cardiomyopathy. Heart Fail Clin 2010, 6(2):129-140.
2. Baig M.K., Goldman J.H., Caforio A.L., Coonar A.S., Keeling P.J., McKenna W.J. Familial dilated cardiomyopathy: cardiac abnormalities are common in asymptomatic relatives and may represent early disease. J Am Coll Cardiol 1998, 31(1):195-201.
3. Crispell K.A., Wray A., Ni H., Nauman D.J., Hershberger R.E. Clinical profiles of four large pedigrees with familial dilated cardiomyopathy: preliminary recommendations for clinical practice. J Am Coll Cardiol 1999, 34(3):837-847.
4. Zachara E., Caforio A.L., Carboni G.P., Pellegrini A., Pompili A., Del Porto G., et al. Familial aggregation of idiopathic dilated cardiomyopathy: clinical features and pedigree analysis in 14 families. Br Heart J 1993, 69(2):129-135.
5. Caforio A.L., Mahon N.G., Baig M.K., Tona F., Murphy R.T., Elliott P.M., et al. Prospective familial assessment in dilated cardiomyopathy: cardiac autoantibodies predict disease development in asymptomatic relatives. Circulation 2007, 115(1):76-83.
6. Macdonald P.S., Keogh A.M., Aboyoun C.L., Lund M., Amor R., McCaffrey D.J. Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure. J Am Coll Cardiol 1999, 33(4):924-931.
7. Packer M., Bristow M.R., Cohn J.N., Colucci W.S., Fowler M.B., Gilbert E.M., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996, 334(21):1349-1355.
8. Packer M., Coats A.J., Fowler M.B., Katus H.A., Krum H., Mohacsi P., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001, 344(22):1651-1658.
9. Remme W.J., Riegger G., Hildebrandt P., Komajda M., Jaarsma W., Bobbio M., et al. The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN). Cardiovasc Drugs Ther 2004, 18(1):57-66.
10. Chandar S., Yeo L.S., Leimena C., Tan J.C., Xiao X.H., Nikolova-Krstevski V., et al. Effects of mechanical stress and carvedilol in lamin A/C-deficient dilated cardiomyopathy. Circ Res 2010, 106(3):573-582.
11. Henry W.L., Gardin J.M., Ware J.H. Echocardiographic measurements in normal subjects from infancy to old age. Circulation 1980, 62(5):1054-1061.
12. Lang R.M., Bierig M., Devereux R.B., Flachskampf F.A., Foster E., Pellikka P.A., et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005, 18(12):1440-1463.
13. Little W.C., Cheng C.P., Mumma M., Igarashi Y., Vinten-Johansen J., Johnston W.E. Comparison of measures of left ventricular contractile performance derived from pressure-volume loops in conscious dogs. Circulation 1989, 80(5):1378-1387.
14. Crispell K.A., Hanson E.L., Coates K., Toy W., Hershberger R.E. Periodic rescreening is indicated for family members at risk of developing familial dilated cardiomyopathy. J Am Coll Cardiol 2002, 39(9):1503-1507.
15. Mahon N.G., Murphy R.T., MacRae C.A., Caforio A.L., Elliott P.M., McKenna W.J. Echocardiographic evaluation in asymptomatic relatives of patients with dilated cardiomyopathy reveals preclinical disease. Ann Intern Med 2005, 143(2):108-115.
16. Mahon N.G., Madden B.P., Caforio A.L., Elliott P.M., Haven A.J., Keogh B.E., et al. Immunohistologic evidence of myocardial disease in apparently healthy relatives of patients with dilated cardiomyopathy. J Am Coll Cardiol 2002, 39(3):455-462.
17. Urhausen A., Kindermann W. Echocardiographic findings in strength- and endurance-trained athletes. Sports Med 1992, 13(4):270-284.
18. Urhausen A., Monz T., Kindermann W. Echocardiographic criteria of physiological left ventricular hypertrophy in combined strength- and endurance-trained athletes. Int J Card Imaging 1997, 13(1):43-52.
19. Michels V.V., Olson T.M., Miller F.A., Ballman K.V., Rosales A.G., Driscoll D.J. Frequency of development of idiopathic dilated cardiomyopathy among relatives of patients with idiopathic dilated cardiomyopathy. Am J Cardiol 2003, 91(11):1389-1392.
20. Packer M. Pathophysiology of chronic heart failure. Lancet 1992, 340(8811):88-92.
21. Cheng J., Kamiya K., Kodama I. Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential. Cardiovasc Drug Rev 2001, 19(2):152-171.
22. Metra M., Giubbini R., Nodari S., Boldi E., Modena M.G., Dei Cas L. Differential effects of beta-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation 2000, 102(5):546-551.
23. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 1992, 327(10):685-691.
24. Pfeffer M.A., Braunwald E., Moye L.A., Basta L., Brown E.J., Cuddy T.E., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992, 327(10):669-677.
25. Vantrimpont P., Rouleau J.L., Wun C.C., Ciampi A., Klein M., Sussex B., et al. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators. J Am Coll Cardiol 1997, 29(2):229-236.
26. Exner D.V., Dries D.L., Waclawiw M.A., Shelton B., Domanski M.J. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1999, 33(4):916-923.
27. Sliwa K., Norton G.R., Kone N., Candy G., Kachope J., Woodiwiss A.J., et al. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure. J Am Coll Cardiol 2004, 44(9):1825-1830.
28. Willenheimer R., van Veldhuisen D.J., Silke B., Erdmann E., Follath F., Krum H., et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 2005, 112(16):2426-2435.
29. Colucci W.S., Kolias T.J., Adams K.F., Armstrong W.F., Ghali J.K., Gottlieb S.S., et al. Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial. Circulation 2007, 116(1):49-56.
30. De Matos L.D., Gardenghi G., Rondon M.U., Soufen H.N., Tirone A.P., Barretto A.C., et al. Impact of 6 months of therapy with carvedilol on muscle sympathetic nerve activity in heart failure patients. J Card Fail 2004, 10(6):496-502.
31. Lowes B.D., Gill E.A., Abraham W.T., Larrain J.R., Robertson A.D., Bristow M.R., et al. Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. Am J Cardiol 1999, 83(8):1201-1205.